GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Lo, Michael K ^a   Jordan, Robert ^b   Arvey, Aaron ^b   Sudhamsu, Jawahar ^b   Shrivastava Ranjan, Punya ^a   Hotard, Anne L ^a   Flint, Mike ^a   McMullan, Laura K ^a   Siegel, Dustin ^b   Clarke, Michael O ^b   Mackman, Richard L ^b   Hui, Hon C ^b   Perron, Michel ^b   Ray, Adrian S ^b   Cihlar, Tomas ^b   Nichol, Stuart T ^a   Spiropoulou, Christina F ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ANTIVIRUS AGENT; GS-5734; NUCLEOSIDE; PRODRUG; RIBONUCLEOTIDE; RNA DIRECTED RNA POLYMERASE; VIRAL PROTEIN;

A-549 CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CHLOROCEBUS AETHIOPS; DRUG EFFECT; EBOLAVIRUS; ENZYMOLOGY; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEK293 CELL LINE; HELA CELL LINE; HUMAN; LIVER CELL; MARBURGVIRUS; METABOLISM; MICROBIAL SENSITIVITY TEST; PARAMYXOVIRIDAE; PNEUMOVIRINAE; SYNTHESIS; TUMOR CELL LINE; VERO CELL LINE; VIROLOGY;

A549 CELLS; ALANINE; ANIMALS; ANTIVIRAL AGENTS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; EBOLAVIRUS; GENE EXPRESSION; HEK293 CELLS; HELA CELLS; HEPATOCYTES; HUMANS; MARBURGVIRUS; MICROBIAL SENSITIVITY TESTS; NUCLEOSIDES; PARAMYXOVIRIDAE; PNEUMOVIRINAE; PRODRUGS; RIBONUCLEOTIDES; RNA REPLICASE; VERO CELLS; VIRAL PROTEINS;

EID: 85014764670     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep43395     Document Type: Article

References (32)

1. Cihlar, T. & Ray, A. S. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res 85, 39-58 (2010).
2. Eltahla, A. A., Luciani, F., White, P. A., Lloyd, A. R. & Bull, R. A. Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance. Viruses 7, 5206-5224 (2015).
3. Cho, A. et al. Synthesis and antiviral activity of a series of 1'-substituted 4-Aza-7,9-dideazaadenosine C-nucleosides. Bioorg Med Chem Lett 22, 2705-2707 (2012).
4. Warren, T. K. et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531, 381-385 (2016).
5. Lo, M. K., Nichol, S. T. & Spiropoulou, C. F. Evaluation of luciferase and GFP-expressing Nipah viruses for rapid quantitative antiviral screening. Antiviral Res 106, 53-60 (2014).
6. Towner, J. S. et al. Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and highthroughput antiviral drug screening. Virology 332, 20-27 (2005).
7. Albarino, C. G., Wiggleton Guerrero, L., Lo, M. K., Nichol, S. T. & Towner, J. S. Development of a reverse genetics system to generate a recombinant Ebola virus Makona expressing a green fluorescent protein. Virology 484, 259-264 (2015).
8. Albarino, C. G. et al. Development of a reverse genetics system to generate recombinant Marburg virus derived from a bat isolate. Virology 446, 230-237 (2013).
9. Afonso, C. L. et al. Taxonomy of the order Mononegavirales: update 2016. Arch Virol 161, 2351-2360 (2016).
10. Rennick, L. J. et al. Live-Attenuated measles virus vaccine targets dendritic cells and macrophages in muscle of nonhuman primates. J Virol 89, 2192-2200 (2015).
11. Zhang, L. et al. Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J Virol 79, 1113-1124 (2005).
12. Hallak, L. K., Spillmann, D., Collins, P. L. & Peeples, M. E. Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J Virol 74, 10508-10513 (2000).
13. Biacchesi, S. et al. Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes. Virology 321, 247-259 (2004).
14. Xu, P. et al. Rescue of wild-type mumps virus from a strain associated with recent outbreaks helps to define the role of the SH ORF in the pathogenesis of mumps virus. Virology 417, 126-136 (2011).
15. Bird, B. H. et al. Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J Virol 82, 2681-2691 (2008).
16. Bergeron, E. et al. Recovery of Recombinant Crimean Congo Hemorrhagic Fever Virus Reveals a Function for Non-structural Glycoproteins Cleavage by Furin. PLoS Pathog 11, e1004879 (2015).
17. Sims, A. C. et al. The small molecule nucleoside prodrug GS-5734 exhibits broad antiviral activity against pathogenic human coronaviruses and related zoonotic strains. In 4th Antivirals Congress (Sitges, Barcelona, Spain, 2016).
18. Xu, X. et al. Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design. Nucleic Acids Res 31, 7117-7130 (2003).
19. Kinsella, E. et al. Sequence determination of the Crimean-Congo hemorrhagic fever virus L segment. Virology 321, 23-28 (2004).
20. Jacome, R., Becerra, A., Ponce de Leon, S. & Lazcano, A. Structural Analysis of Monomeric RNA-Dependent Polymerases: Evolutionary and Therapeutic Implications. PLoS One 10, e0139001 (2015).
21. Uebelhoer, L. S. et al. High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses. Antiviral Res 106, 86-94 (2014).
22. Bird, B. H., Albarino, C. G. & Nichol, S. T. Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease. Virology 362, 10-15 (2007).
23. Reed, L. J. M. H. A simple method of estimating fifty percent endpoints. Am J Hygiene 27, 493-497 (1938).
24. Aljofan, M., Porotto, M., Moscona, A. & Mungall, B. A. Development and validation of a chemiluminescent immunodetection assay amenable to high throughput screening of antiviral drugs for Nipah and Hendra virus. J Virol Methods 149, 12-19 (2008).
25. Hensley, L. E., Dyall, J., Olinger, G. G. Jr. & Jahrling, P. B. Lack of effect of lamivudine on Ebola virus replication. Emerg Infect Dis 21, 550-552 (2015).
26. Chiang, C. F., Lo, M. K., Rota, P. A., Spiropoulou, C. F. & Rollin, P. E. Use of monoclonal antibodies against Hendra and Nipah viruses in an antigen capture ELISA. Virol J 7, 115 (2010).
27. McMullan, L. K. et al. The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus. Antiviral Res 125, 71-78 (2016).
28. Mohr, E. L. et al. Inhibitors of cellular kinases with broad-spectrum antiviral activity for hemorrhagic fever viruses. Antiviral Res 120, 40-47 (2015).
29. Chiang, C. F., Albarino, C. G., Lo, M. K. & Spiropoulou, C. F. Small interfering RNA inhibition of Andes virus replication. PLoS One 9, e99764 (2014).
30. Halpin, K., Bankamp, B., Harcourt, B. H., Bellini, W. J. & Rota, P. A. Nipah virus conforms to the rule of six in a minigenome replication assay. J Gen Virol 85, 701-707 (2004).
31. Shaner, N. C. et al. A bright monomeric green fluorescent protein derived from Branchiostoma lanceolatum. Nat Methods 10, 407-409 (2013).
32. Edgar, R. C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 32, 1792-1797 (2004).